Amyloid precipitation in biofluids using a structure-specific chemical antibody

Margarida Rodrigues

Department of Chemistry, University of Cambridge <https://orcid.org/0000-0001-6364-7125>

Payel Bhattacharjee

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg

Ann Brinkmalm

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg

Dung Do

Department of Chemistry, Indiana University

Colin Pearson

Department of Chemistry, Indiana University

Suman De

University of Cambridge

Aleks Ponjavic

University of Leeds <https://orcid.org/0000-0002-7561-1127>

Juan Varela

Department of Chemistry, University of Cambridge

Francesco Ruggeri

University of Cambridge <https://orcid.org/0000-0002-1232-1907>

Isabelle Baudrexel

Department of Chemistry, University of Cambridge

Ji Lee

Department of Chemistry, University of Cambridge

Alexander Carr

Department of Chemistry, University of Cambridge

Klara Kulenkampff

Department of Chemistry, University of Cambridge

Tuomas Knowles

University of Cambridge <https://orcid.org/0000-0002-7879-0140>

Henrik Zetterberg

Sahlgrenska Academy at the University of Gothenburg

Thomas Snaddon

Indiana University <https://orcid.org/0000-0003-1119-0332>

Sonia Gandhi

University College London

Steven Lee

University of Cambridge

David Klenerman (✉ dk10012@cam.ac.uk)

University of Cambridge <https://orcid.org/0000-0001-7116-6954>

Article

Keywords: neurodegenerative disease, amyloid precipitation, biofluids

Posted Date: November 5th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-81521/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Nature Chemistry on July 7th, 2022. See the published version at <https://doi.org/10.1038/s41557-022-00976-3>.

Title

Amyloid precipitation in biofluids using a structure-specific chemical antibody

M. Rodrigues^{1,2}, P. Bhattacharjee^{3,4}, A. Brinkmalm^{3,4}, D. T. Do⁵, C. M. Pearson⁵, S. De^{1,2}, A. Ponjavic^{1,6,7}, J. A. Varela^{1,8}, F. S. Ruggeri¹, I. Baudrexel¹, J. E. Lee^{1,9}, A. R. Carr¹, K. Kulenkampff^{1,2}, T. P. J. Knowles¹, H. Zetterberg^{3,4,10,11}, T. N. Snaddon^{5*}, S. Gandhi^{10,12*}, S. F. Lee^{1*} and D. Klenerman^{1,2*}

¹ Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK

² UK Dementia Research Institute, University of Cambridge, Cambridge, CB2 0XY, UK.

³ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, S-431 80 Mölndal, Sweden

⁴ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

⁵ Department of Chemistry, Indiana University, 800 E. Kirkwood Ave. Bloomington, IN 47405, USA.

⁶ School of Physics and Astronomy, University of Leeds, Leeds, UK

⁷ School of Food Science and Nutrition, University of Leeds, Leeds, UK

⁸ School of Biology, University of St Andrews, North Haugh, St Andrews KY16 9ST, UK

⁹ Department of Physics and Biology, University of York, Heslington York YO10 5DD, UK

¹⁰ Department of Neurodegenerative Disease, UCL Institute of Neurology, London, WC1N 3BG, UK

¹¹ UK Dementia Research Institute at UCL, London, UK

¹² The Francis Crick Institute, 1 Midland Road, King's Cross, London, NW1 1AT, UK

* Joint corresponding authors

Abstract

The composition of soluble toxic protein aggregates formed *in vivo* is currently unknown in neurodegenerative diseases, due to their ultra-low concentration in human biofluids and their high degree of heterogeneity. We introduce the structure-specific chemical antibody; a Y shaped, bioinspired small molecule with a dimeric region to mimic avidity, and an attachment region to mimic the Fc region. Our probe, capture molecule for amyloid precipitation (CAP-1), consists of a derivative of Pittsburgh compound B (dimer) to target the cross β -sheets of amyloids and a biotin moiety for surface immobilization. By coupling CAP-1 to magnetic beads, we *targeted* the amyloid structure of protein aggregates in human cerebrospinal fluid, *isolated* them for analysis and then characterised them using single-molecule fluorescence imaging and mass spectrometry. AP allows unbiased determination of the molecular composition and structural features of the *in vivo* aggregates, formed in neurodegenerative diseases, that are present in biofluids.

Introduction

α -Synuclein, amyloid- β and tau are examples of proteins that self-aggregate in cross β -sheets motifs, and are present in Lewy bodies, amyloid plaques, and tau tangles, respectively¹. These cross β -sheets (or amyloid structures) are found in the brains of people with neurodegenerative diseases such as Parkinson's and Alzheimer's disease²⁻⁴. Importantly, brain extracts containing misfolded amyloid- β from patients with Alzheimer's disease (AD) and preformed α -synuclein fibrils induced cerebral β -amyloidosis and α -synuclein propagation, respectively and associated pathologies in mice⁵⁻⁸. On the other hand, depletion of aggregates from an AD brain suppressed *in vivo* seeding capability⁹ reinforcing the idea that the induction of pathology is likely governed by the structure and concentration of the aggregate seeds^{10,6} and highlights the importance of studying the aggregated protein as opposed to its monomeric counterpart.

The exact mechanism by which protein aggregates lead to progressive loss of neuronal cells and result in subsequent pathophysiologic effects like dementia and movement disorders remains poorly understood. It is known that subtle differences in amino acid content result in major structural changes that have an impact in the pathophysiology of these diseases¹¹⁻¹⁴. Also, *in vitro* studies have revealed that protein aggregation is a dynamic process where a wide range of aggregates with variable sizes¹ and hydrophilicities¹⁵ are formed, and that the aggregates become more toxic when they acquire cross β -sheets structure^{1,16}. Small soluble protein aggregates (< 200 nm) of α -synuclein and amyloid- β as well as, late insoluble tau aggregates are implicated in cellular cytotoxicity¹⁷⁻²³. Moreover, it was recently reported that small soluble amyloid- β aggregates induced extensive membrane permeability while larger β -sheet containing aggregates were most effective at causing an inflammatory response in microglia cells²². These findings were replicated in a recent study of the aggregates present in cerebrospinal fluid (CSF) of patients at different stages of AD²⁴. The aggregates in the CSF of mild cognitively impaired patients induced more membrane permeabilisation, while larger β -sheet aggregates present in the CSF of AD patients were more effective at inducing inflammation²⁴. Together these studies reinforce the idea that aggregates of

different size and structure trigger different toxic mechanisms and that the relative proportion of these different aggregates change during the development of the disease.

It is now understood that AD develops before the manifestation of clinical symptoms, so it is important to develop new diagnostic methods in readily available biofluids such as blood, urine and CSF. In particular, CSF is one of the major clearance systems and provides an accessible biofluid that can be used to assess extracellular protein aggregates. However, the protein aggregates present in CSF are at very low (sub-picomolar) concentrations and they are very heterogeneous in size^{25,26}. These two factors have significantly hindered the development of suitable tools to isolate and study protein aggregates from human biofluids. New methods are needed to isolate and characterise the low levels of aggregates present in human biofluids in order to better understand how compositional and structural differences in these aggregates impact cellular toxicity and contribute to disease pathogenesis. This is a fundamental step toward the development of effective therapeutic strategies and for early diagnosis of disease.

Until recently, proteins aggregates implicated in neurodegeneration have largely been characterised using capture techniques based on antibodies or aptamers^{27–30}. However, both antibody and aptamer capture strategies have a fundamental limitation that they only target aggregates of a selected protein as well as having other problems such as epitope accessibility on misfolded proteins, inefficient targeting if the aggregated proteins contains post-translational modifications, and difficulties to recognise aggregates composed by oligomers formed by more than one type of protein^{31,32}. To address these issues we have developed a structure specific chemical antibody designed to selectively bind cross-beta sheet motifs instead of a specific protein epitope, allowing detection of the range of protein aggregates associated with neurodegenerative diseases^{26,33}. We have named this new molecule capture molecule for amyloid precipitation (CAP-1). Protein aggregates can be precipitated from solution by attaching CAP-1 to magnetic beads, which we refer to as amyloid precipitation (AP). This AP approach enables an array of molecular and cellular techniques, ranging from single-molecule imaging to cytotoxicity studies, to be performed to characterise the structural and functional properties of protein aggregates.

Results

Rational design and characterization of a bio-inspired amyloid-specific probe

The design of CAP-1 was inspired by the structure of antibodies due to their natural high affinity to target specific molecules, based on their Y-shaped structure with two binding sites. This structure specific chemical antibody contains structural elements of thioflavin T (ThT) for its photophysical and optical properties^{33,34} and structural elements of Pittsburgh compound B (PiB) for its increased affinity to β -sheet structures compared with ThT^{35,36}, namely the benzothiazole group (PiB).

The synthesis of CAP-1 was achieved using established methods; see Fig. 1a for structure and SI.1-9 for synthesis details. The trimeric species has two β -sheet binding sites for increased avidity (as previously described for a dimeric version of ThT³⁷) and has a third site for immobilisation, in this specific implementation *via* biotin – streptavidin binding.

After initial spectral characterisation of CAP-1, $\lambda_{\text{ex-em}}$ 355-440 nm (SI.10) we evaluated the binding of CAP-1 to α -synuclein monomers, oligomers and fibrils (Fig. 1b-d). CAP-1 binds to oligomers and fibrils but not monomers, see Fig.1b-d and SI.12. CAP-1, like ThT³⁸, is suitable for total internal reflection fluorescence microscopy (TIRFM), and can be used to monitor the aggregation reaction, from small early stage aggregates ($t > 4\text{h}$) to long mature fibrils ($t > 24\text{h}$) (Fig.1c). The progressive increase in fluorescence intensity (Fig. 1d and SI.12) with increased incubation measured by bulk fluorescence further demonstrates CAP-1 specificity towards cross β -sheets.

α -synuclein was selected as the model amyloid protein throughout this work but we also achieved similar results using other amyloid proteins such as $\text{a}\beta_{42}$ and tau aggregates (SI.13). The binding of CAP-1 to these protein aggregates further supports the specificity towards cross β -sheet regardless of protein sequence, highlighting the value of using CAP-1 to target a ‘structural epitope’. Such non-biased approach is key since the composition of *in vivo* aggregates remains elusive.

Finally, we determined the binding affinity of CAP-1 to α -synuclein and compared this affinity with that of ThT using bulk fluorescence and mature sonicated fibrils (average length 200 nm), to avoid heterogeneity in the structure and size of the aggregates, see SI.14. Using an initial concentration of 100 nM α -synuclein we obtained a K_d (CAP-1) = 82.63 ± 11.70 nM and K_d (ThT) = 3962 ± 352 nM (Fig.1e), representing a 50-fold increase in affinity of CAP-1 compared to ThT. Dissociation constants often depend on the approach used and previous studies reported K_d of ThT for α -synuclein fibrils from 588 nM to 100 μ M^{39,40}. In a study using a similar methodology to ours but using $a\beta_{40}$ fibrils instead of α -synuclein the K_d was 2.3 μ M³⁷. The significant increase in CAP-1 affinity towards amyloids compared to ThT can be explained by the combination of two key factors: CAP-1 being a dimer, as previously described avidity increases affinity³⁷ and the absence of the *N*-methylated benzothiazole moiety (SI.1) as seen for PiB^{35,36}.

Figure 1 – Design and characterization of a bio-inspired structure-specific chemical antibody. **(a)** CAP-1 chemical structure. In purple the amyloid binding regions and in blue, biotin used for surface attachment *via* streptavidin binding. **(b)** Illustrative diagram highlighting the selective affinity of CAP-1 to cross β -sheets present in early stage aggregates and fibrils but not in monomers. **(c)** TIRFM images of α -synuclein aggregation at 0h, 8h (red circles highlighting oligomers) and 24h using 5 μ M CAP-1, λ_{ex} 405 nm. Scale bar = 5 μ m, inset scale bar = 2 μ m. **(d)** Fluorescence intensity increase of CAP-1 (20 μ M) upon binding to 10 μ M α -synuclein at different time points of the aggregation reaction using λ_{ex} 355 nm. The error bar represents the SD of the maximum fluorescence intensity between two independent experiments. The p -value corresponds to the result of a one-way ANOVA, and Tukey's post hoc comparison. ** p <0.0017, *** p =0.0007, n.s. p >0.05. **(e)** Binding affinity of CAP-1 and ThT to α -synuclein. Increasing amounts of CAP-1 or ThT were added to 100 nM α -synuclein. The K_d was obtained by fitting the experimental points to a hyperbolic curve (specific binding), K_d (CAP-1) = 82.63 ± 11.70 and K_d (ThT) = 3962 ± 352 nM.

Capture of protein aggregates using CAP-1 – Method of amyloid-precipitation

Following the characterization of CAP-1 binding to α -synuclein, we designed a protocol for isolation of protein aggregates from solution, which we have named amyloid precipitation (AP).

The schematic of AP is outlined in Fig. 2a-b. After the conjugation of CAP-1 with magnetic streptavidin-coated beads (Fig. 2a), the beads are added to a solution containing protein aggregates such as recombinant α -synuclein solution or a biofluid. After 2h at 4°C with gentle mixing, the beads are separated using a magnet and both fractions ('beads' and 'depleted') are analysed by TIRFM (Fig. 2c) and bulk fluorescence (Fig. 2d).

Fig. 2c shows conjugated beads with CAP-1 after AP using α -synuclein fibrils (right) or PBS (left). The presence of fibrils (right panel) attached to the beads is visible by the 'hairy' appearance of the beads and highlighted in the magnified bead, and contrasts with the plain look of beads without protein (left panel). Despite the heterogeneous bead-to-fibril attachment, some beads contain many small fibrils and other fewer but longer fibrils, there is a significant difference in the diameter (measured as fluorescence intensity profile) between beads in the presence or absence of α -synuclein fibrils, 105 nm ($p = 0.0002$) confirming the successful binding of fibrils to beads (see SI.15).

In Fig. 2d we tested the efficacy of AP towards α -synuclein fibrils (purple) *versus* α -synuclein monomers (orange) (see SI.16 for representative fluorescent spectra of both fractions). The low fluorescence intensity detected for the supernatant of both samples, 11% for fibrils and 3% for monomers, respectively, reflects the presence of residual CAP-1 molecules released from the beads during the incubation and as expected is higher for the sample containing fibrils. The difference between beads incubated with α -synuclein fibrils (100%, purple) and beads with α -synuclein monomers (33%, orange) highlights the absence of cross β -sheet in the monomeric solution and corresponds to the fluorescence of CAP-1 alone. The fluorescence intensity for the samples,

beads+CAP-1+monomers (Fig. 2d orange) and beads+CAP-1+PBS (blank, see SI.16), is the same for both beads and supernatant, confirming that CAP-1 does not bind to monomers (see SI.16). Overall, the fluorescence increase between the supernatant (11%) and beads (100%) for the α -synuclein fibrils sample demonstrates the successful pulldown (and concentration) of aggregates by the beads.

In both TIRFM (Fig. 2c) and bulk (Fig. 2c) measurements, detection of protein aggregates is based on CAP-1 intrinsic fluorescence, highlighting its ability to strongly bind (capture) aggregates and work as optical readout for the presence of β -sheets. We also used atomic force microscopy (AFM), an orthogonal non-optical technique, to confirm the successful binding of α -synuclein fibrils to CAP-1-beads (SI.17). As shown in the 3D (height) image fibrils localize preferentially close to the beads (SI.17a), once more demonstrating the preference of protein aggregates to CAP-1 coated beads.

Until now, we have used mature α -synuclein fibrils (sonicated 200 nm, non-sonicated $>1 \mu\text{m}$) as a model of protein aggregation to test AP. However, in biological fluids such as cerebrospinal fluid (CSF) the amyloids present are smaller. These ‘early stage’ aggregates, or oligomers, have been shown to be much smaller than the optical diffraction limit ($\sim 250\text{nm}$)³⁸ and confirmed to be approximately tens of nanometres in size using higher resolution methods such as AD-PAINT¹⁵ and AFM⁴¹. For this reason we used α -synuclein aggregates collected at the 8 hour time point to maximize the number of oligomers^{15,16} and to validate the AP method for use in a biological context. We used EM to characterize aggregates present at 8h (SI.16) and confirmed their sub-diffraction limit size ($\sim 30 \text{ nm}$). The results in Fig. 2e show the number of fluorescent puncta before and after amyloid precipitation, $6.0 \times 10^{-2}/\mu\text{m}^2$ and $3.6 \times 10^{-4}/\mu\text{m}^2$, respectively (see SI.19 TIRFM images). In the presence of CAP-1 the number of protein aggregates in solution after pulldown is reduced to background levels (Fig. 2e, grey column - $4.2 \times 10^{-4} \pm 2.3 \times 10^{-4}/\mu\text{m}^2$). In the absence of CAP-1

there was partial removal of aggregates (see SI.19) suggesting unspecific binding to the beads but negligible compared to the virtually complete depletion, 99.4%, in the presence of CAP-1.

Next we investigated the use of mass spectrometry (MS) to quantify the amount of α -synuclein enriched on the beads after pulldown as MS will allow identification of molecular composition of the amyloids captured using AP. For this, we used high-resolution parallel reaction monitoring (PRM) mass spectrometry (MS). After AP, α -synuclein was eluted from the beads and digested using trypsin, converting full length α -synuclein into small peptides, namely α -syn₁₃₋₂₁, α -syn₃₅₋₄₃, α -syn₄₆₋₅₈, α -syn₆₁₋₈₀, and α -syn₈₁₋₉₆, see Fig. 2. The PRM-MS spectrum in Fig. 2g shows the relative abundance of each peptide. In order to confirm the specificity of CAP-1, we compared the presence and absence of CAP-1 during the AP. In the presence of CAP-1 the amount of individual peptides was 5 to 13 times higher, depending on the peptide, than without CAP-1 (Fig. SI.21). This is in agreement with TIRFM results (Fig. 2e).

Figure 2 – Amyloid-precipitation using CAP-1. **(a)** Magnetic Dynabeads coated with streptavidin conjugated with CAP-1 via biotin moiety. **(b)** Outline of the amyloid-precipitation (AP) method. Functionalised beads with CAP-1 are incubated with an amyloid containing solution. After incubation beads bound to proteins aggregates are isolated using a magnet. Both fractions, depleted (supernatant) and enriched fraction (beads) can be analysed by bulk fluorescence and TIRFM. **(c)** TIRFM of Dynabeads Streptavidin C1 coated with CAP-1 and in the presence (right panel) or absence (left panel) of 10 μM α -synuclein fibrils (right panel) using λ_{ex} 405 nm. α -synuclein fibrils can be seen attached to the beads creating a ‘hairy’ bead look (right panel detail) or in other cases as a single long and thick spike. In the absence of protein aggregates (left panel) beads have a plain look. Scale bar = 3 μm . **(d)** Bulk fluorescence intensity (normalised) of beads and supernatant after AP using 10 μM α -synuclein, (■) 100 % of monomers and (■) sonicated fibrils (5 days incubation), λ_{ex} 355 nm and $\lambda_{\text{em_max}}$. SN represents the supernatant or ‘depleted’ fraction and B the ‘beads’ fraction.

The error bar represents the SD of the maximum fluorescence intensity between two independent experiments (each made in triplicate) and differences between two groups were analysed using unpaired two-tailed Student's t test, *p=0.0345, **p=0.0062 and ***p=0.0004. (e) Depletion of α -synuclein oligomers (time point 8h of α -synuclein aggregation reaction) by AP and quantification of aggregates left in the supernatant (depleted fraction). Plotted is the fluorescent puncta counts $\times 10^2/\mu\text{m}^2$ for the sample before and after AP using TIRFM. AP captures approximately ~100% of oligomers in solution. The error bar represents the SD of the number of fluorescence puncta between at least 27 fields of view for one representative experiment (see SI.19 for TIRFM images) (f) Outline of AP followed by on bead digestion. α -synuclein₁₃₋₂₁ peptide fragment ion PRM spectrum in the presence (right) and absence (left) of CAP-1, recovered after AP from a solution containing 1 nM total α -synuclein (<50 pM oligomers).

Amyloid-precipitation followed by PRM mass spectrometry of α -synuclein spiked in human CSF

AP is an unbiased method to capture amyloid protein from solution, allowing subsequent mass spectrometry identification of proteins present in such aggregates^{42,43}. As CSF is a complex biofluid made of more than two thousand different proteins⁴⁴, we firstly determined the sensitivity of CAP-1-beads to capture known amounts of α -synuclein spiked in CSF.

Increasing amounts of either purified α -synuclein monomers ($t = 0$ hours) or α -synuclein mixture of monomers ($>95\%$) and oligomers ($<5\%$)¹⁶ ($t = 8$ hours), were spiked in control CSF, see Fig. 3a for the outline of the experiment and SI.22 for TIRFM representative images. After AP, the beads were trypsin-digested and analysed by PRM-MS. In Fig. 3b the amount of α -synuclein₁₃₋₂₁ peptide recovered as a function of the initial α -synuclein concentration spiked is shown. Naturally occurring α -synuclein oligomers present in CSF were undetectable (see Table 3-8 for list of proteins pulled down). For concentrations equal to and below 1 nM, monomers were not detected, while in 1 nM of mixed species 28 femtomoles (28 pM) of α -syn₁₃₋₂₁ captured were detected (SI.21 for other peptides). For α -synuclein concentrations higher than 1 nM, the increase in α -syn₁₃₋₂₁ detected is linear and about three times higher for the mixed species sample than for the monomers (Fig. 3b). CAP-1-beads captured 0.6% of total α -synuclein monomers (orange) spiked in CSF and 2.3% of total α -synuclein mixture (monomers $>95\%$ and oligomers $<5\%$, purple). This means that almost no monomers in solution are captured while approximately 50% (2.3% out of $<5\%$) of the oligomers added to CSF are captured. For this reason, the 3-fold change in the total amount of α -syn₁₃₋₂₁ recovered (Fig. 3b) represents a large difference in capture affinity between the monomer which is present at high concentration and low concentration of aggregated α -synuclein. This result confirms the specificity of AP in capturing protein aggregates compared to the monomers in complex biofluids such as CSF.

The proteins captured using CAP-1 beads should be enriched in amyloid prone proteins or contain proteins in the CSF that bind amyloid proteins³². Using PASTA 2.0⁴⁵ and RFAmyloid⁴⁶, two highly cited web servers for the prediction of protein aggregation from sequence we observed an increase in the total number of amyloid-prone proteins when using CAP-1 compared to unmodified beads (see SI Table 9). As expected, in the presence of CAP-1 there is an increase in the total β -strand content of captured proteins (25-26%) compared to not using the capture molecule (19%), providing further computational evidence of the ability of CAP-1 to select β -sheet containing proteins (see Table 1 and 2).

To evaluate the efficiency of AP in removing toxic amyloid species from CSF we used a sensitive membrane permeability assay previously developed¹⁸ (see Fig. 3c for outline of the experiment). CSF is diluted in a solution containing Ca^{2+} and then added to liposomes containing a Ca^{2+} -dependent dye encapsulated. If CSF contains amyloids/oligomers that cause membrane permeability, Ca^{2+} enters the liposome resulting in increased fluorescence. In Fig. 3d, the average Ca^{2+} influxes for CSF before AP (purple), CSF after AP ('depleted' fraction) (white) and CSF after AP without CAP-1 (white with purple dots) using the same CSF as in Fig. 3b it is plotted. AP removed most of the CSF proteins responsible for Ca^{2+} influx, reducing membrane permeability from 27% to 6%. Having established that AP is able to remove amyloid proteins from control CSF (Fig. 3b-d), we then decided to use CSF from Parkinson's disease (PD) patients in a separate set of experiments (Fig. 3e-f). TIRFM images showed a significant decrease in the number of ThT active species after AP Fig. 3g (left panels) and we found that there was a reduction of ~50% in Ca^{2+} influx. This demonstrates that AP can capture amyloid aggregates from PD CSF. It is worth noting that there is non-specific binding to the beads without CAP-1 that leads to some aggregate capture and a small reduction in membrane permeability (Fig. 3d-e middle column).

Figure 3 – Amyloid-precipitation of CSF spiked with recombinant α -synuclein oligomers. **(a)** Outline of the experiment. Known amounts of recombinant α -synuclein monomers or mixture of oligomers + monomers (<95%) are spiked into control CSF. **(b)** Quantification of α -synuclein₁₃₋₂₁ peptide recovered from on-bead digestion after AP using PRM-MS. Results were plotted as amount of α -synuclein₁₃₋₂₁ peptide recovered in fmol as a function of the initial α -synuclein concentration used for AP in pM. from α -synuclein monomers (—●—) and from α -synuclein mixture (oligomers+monomers) (—●—). **(c)** Outline of the membrane permeabilization assay. **(d)** Average Ca^{2+} influx in control CSF (used in **b**) before and after AP, and after AP in the absence of CAP-1. Mean and SD for the average Ca^{2+} influx for at least 10 to 15 fields of view for each sample for one representative experiment. **(e)** Average Ca^{2+} influx of PD

CSF sample before and after AP in the presence of CAP-1 and, after AP in the absence of CAP-1. Mean and SD for the average Ca^{2+} influx of five independent CSF samples (5 different patients, 10 to 15 fields of view used for sample) and p -value from a one-way ANOVA, and Tukey's post hoc comparison. *** $p < 0.001$, * $p = 0.0255$. (f) Example of TIRFM image of PD CSF sample before (left) and after (right) AP, $\lambda_{\text{ex}} 405 \text{ nm}$ and $5 \mu\text{M ThT}$.

Conclusions

Protein aggregates have been known to be implicated in neurodegenerative diseases for more than three decades⁴⁷. Yet, despite much progress there are still significant technological limitations in isolating and characterising the intermediate small species that are formed during the development of disease, this is due to the low abundance, small size and, heterogeneity in conformation and composition of the aggregates^{48–51}. Traditional immunocapture/immune recognition approaches have improved in being able to target misfolded/aggregated proteins but are not capable of distinguishing between aggregates of different structures that may have very different properties and toxicities⁵².

In this study, we presented the synthesis and characterisation of a structure specific chemical antibody designed to capture the protein aggregates associated with neurodegeneration from solution. This molecule has been specifically developed to bind and isolate a target molecule based on secondary structure, the presence of β -sheets, using chemical head groups that form the basis of PET ligands^{53,54}. Previous studies have made use of dimerised ligands (protein/peptide^{55,56} or ThT³⁷) as a way to improve binding affinity to a particular target molecule. To the best of our knowledge, this is the first study to exploit the increased affinity of dimerised ligands in order to enable isolation/precipitation of the target species based on its structure rather than its protein composition.

The CAP-1 structure was successfully designed and then demonstrated to bind and isolate aggregates with amyloid structure (oligomers and fibrils of $\alpha\beta_{42}$, tau and α -synuclein), but crucially not monomers, using synthetic aggregates. However, it is also critical to demonstrate translational relevance. *In vivo*, the complexity of the biofluids that surround the CNS (CSF) and the brain tissue itself makes the detection of small amyloids a major challenge⁵⁷. We demonstrated the sensitive detection of amyloid containing aggregates can be performed in CSF by amyloid pulldown using CAP-1, followed by bead digestion and detection by mass spectrometry. We observed an increased number of amyloid-prone proteins when using CAP-1 compared to plain beads and an increase in

the total content of β -strand highlighting the strength of our method AP in enriching β -sheet containing proteins (see Table 1 and 2).

This new capability for unbiased detection and capture of amyloids, coupled with a mass spectrometry approach to provide the molecular composition is a powerful combination because it has the potential to define the amyloids present in the brain, CSF and other biofluids.

The ability of disease causing aggregates (containing β -sheets) to cause membrane permeabilization has been previously correlated with their cytotoxic potential^{18,22}. Herein, we demonstrated that we could capture the aggregates responsible for membrane permeabilisation present in CSF, reinforcing the idea that AP is an efficient tool to deplete toxic aggregates from biofluids.

Importantly, in AP the beads contain negligible monomers and, since it is possible to remove the captured aggregates from the beads, this approach allows further characterization of the human derived aggregates and cytotoxicity experiments to be performed.

Further improvements to the design of the capture molecule are possible by optimising the linker length, head groups and synthesising multimeric molecules to further improve the sensitivity and selectivity of amyloid precipitation^{58,59}. There may also be significant advantages in this approach in terms of stability and resistance to degradation compared to conventional antibodies⁶⁰⁻⁶².

In conclusion, we have successfully developed a new molecule inspired by the trimeric shape of an antibody to target all aggregates containing cross-beta sheet motifs present in complex biofluids. CAP-1 has two binding sites to improve avidity and a third moiety to enable surface immobilisation and therefore capture of aggregates based on their structure, but not their protein composition. This simple and versatile method allows the identification of molecular components of aggregates, using mass spectrometry. Overall, this structure-based approach will pave the way to understanding the exact molecular species responsible for neurodegeneration in humans and consequently hasten development of simple and robust early diagnosis methods.

Methods

Synthesis of N-biotinylated bis-benzothiazole: CAP-1

(A) *bis*-Mesylate:

To a solution of *diol* (1.47 g, 5.0 mmol, 1.0 equiv.) in anhydrous CH₂Cl₂ (10 mL) was added Et₃N (2.53 mL, 18.0 mmol, 3.6 equiv) at 0 °C. A solution of methanesulfonyl chloride (1.01 mL, 13.0 mmol, 2.6 equiv.) in CH₂Cl₂ (5 mL) was then added dropwise. The reaction was allowed to warm to room temperature (rt) and stirred for an additional 18 h. Aqueous hydrochloric acid

(1 N, 100 mL) was added slowly and the reaction mixture extracted with CH₂Cl₂ (4 × 60 mL). The combined organic layers were washed with saturated sodium bicarbonate solution (50 mL) and brine (60 mL), dried over Na₂SO₄, and concentrated under reduced pressure to give the *bis*-mesylate (**A**) (1.57 g, 3.50 mmol, 70%) as a colourless oil. IR (Film): 2974, 2939, 2874, 1693, 1682, 1545, 1479, 1456, 1416, 1392, 1247, 1172, 1069, 972, 920, 862 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ = 4.33 (m, 4H), 3.70 (m, 4H), 3.59 (m, 4H), 3.44 (m, 4H), 3.03 (s, 6H), 1.43 (s, 12H). ¹³C NMR (126 MHz, CDCl₃): δ = 155.3, 79.9, 69.9, 68.8, 47.7, 37.6, 28.4. HRMS (EI): m/z calcd for [M+Na] C₁₅H₃₁NNaO₁₀S₂ 472.1281. Found 472.1275

(B) Boc-protected *bis*-benzothiazole:

Sodium hydride (60% in oil, 19 mg, 0.44 mmol, 2.2 equiv) was added in one portion to a solution of 2-(4-(dimethylamino)phenyl)benzo[*d*]thiazol-6-ol (110 mg, 0.4 mmol, 2.0 equiv) in DMF (5 mL) at rt. The suspension was stirred for 1 h giving a colourless solution to which the *bis*-mesylate **A** (90 mg, 0.2 mmol, 1.0 equiv) was added then heated to 80 °C for 18 h. After cooling to rt, H₂O (15 mL) was added with vigorous stirring. The resulting precipitate

was collected by filtration, washed with water (10 mL) and Et₂O (10 mL) to give the Boc-protected *bis*-benzothiazole (**B**) (64 mg 0.08 mmol, 40%) as white solid. m.p.: 122–124 °C. IR (Film): 2931, 1684, 1608, 1560, 1410, 1365, 1264, 1226, 1130, 1065, 1006, 967, 943, 864 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ = 7.91 – 7.81 (m, 6H), 7.31 – 7.24 (m, 2H), 7.03 (dd, *J* = 8.9, 2.5 Hz, 2H), 6.69 (d, *J* = 8.6 Hz, 4H), 4.10 (d, *J* = 4.8 Hz, 2H), 3.84 – 3.76 (m, 4H), 3.72 – 3.62 (m, 4H), 3.56 – 3.44 (m, 4H), 3.01 (s, 12H), 1.45 (s, 9H). ¹³C NMR (126 MHz, CDCl₃): δ = 166.6, 156.2, 155.5, 151.8, 149.1,

135.7, 128.5, 122.7, 121.6, 115.4, 111.7, 105.4, 79.6, 70.1, 69.5, 69.4, 68.1, 48.0, 47.8, 40.1, 28.5. HRMS (EI): m/z calcd for $[M+H]^+$ $C_{43}H_{52}N_5O_6S_2$ 798.3359. Found 798.3383.

(C) NH *bis*-benzothiazole:

Boc-protected *bis*-benzothiazole (**B**) (64 mg 0.08 mmol, 1 equiv.) was added to a solution of HCl (4 M in MeOH, 3 mL) at rt. After 1 h, aqueous NaOH (3 M, 10 mL) and EtOAc (10 mL) were added and the layers separated. The aqueous layer was further extracted with EtOAc (2×10 mL) and the combined organic layers dried over Na_2SO_4 and concentrated to give the NH *bis*-benzothiazole (**C**) (55 mg, 80 mmol, 99%)

as light yellow solid. m.p.: 168–170 °C. IR (Film): 3401, 2917, 1608, 1560, 1531, 1285, 1263, 1124, 1006, 967, 941, 818 cm^{-1} . 1H NMR (400 MHz, $CDCl_3$): 7.86 (d, $J = 8.6$ Hz, 4H), 7.83 (d, $J = 8.9$ Hz, 2H), 7.27 (d, $J = 2.5$ Hz, 2H), 7.03 (dd, $J = 8.9, 2.5$ Hz, 2H), 6.70 (d, $J = 8.6$ Hz, 4H), 4.12 (t, $J = 4.7$ Hz, 4H), 3.82 (t, $J = 4.7$ Hz, 4H), 3.68 (t, $J = 5.2$ Hz, 4H), 3.02 (s, 12H), 2.88 (t, $J = 5.2$ Hz, 4H). ^{13}C NMR (126 MHz, $CDCl_3$): $\delta = 166.6, 156.2, 151.9, 149.1, 135.8, 128.5, 122.7, 121.6, 115.4, 111.7, 106.1, 106.1, 105.4, 70.5, 69.6, 68.0, 49.1, 40.2, 29.7$. HRMS (EI): m/z calcd for $[M+H]^+$ $C_{38}H_{44}N_5O_4S_2$ 698.2835. Found 698.2852.

(D) N-Biotinylated bis-benzothiazole:

To a solution of biotin (49 mg, 0.2 mmol, 1 equiv) in anhydrous DMF (2 mL) was added iPr_2NEt (452 μL , 0.26 mmol, 1.3 equiv) and benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP, 135 mg, 0.26 mmol, 1.3 equiv). After 30 min, the amine **C** (140 mg, 0.2 mmol, 1 equiv) and iPr_2NEt (350 μL , 1.0 equiv) in anhydrous DMF (1 mL) was added dropwise. After 18 h, saturated NH_4Cl (10 mL) was added and the

mixture extracted with EtOAc (3×5 mL). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography [SiO_2 , Methanol– CH_2Cl_2 , 1:8] to give N-biotinylated bis-benzothiazole (**CAP-1**) (**D**) (56 mg, 0.06 mmol, 30%) as a light yellow solid. m.p.: 120–122 °C. IR (Film): 3258, 2929, 1699, 1606, 1560, 1533, 1491, 1366, 1264, 1211, 1126, 1067, 941, 820 cm^{-1} . 1H NMR (400 MHz, $CDCl_3$): $\delta = 7.88$ (d, $J = 8.9$ Hz, 4H), 7.85 (d, $J = 8.9$, 2H), 7.84 (d, $J = 8.9$, 2H), 7.31 (d, $J = 2.5$ Hz, 1H), 7.28 (d, $J = 2.5$ Hz, 1H), 7.04 (dd, $J = 8.9, 2.5$ Hz, 1H), 7.03 (dd, $J = 8.9, 2.5$ Hz, 1H),

6.73 (d, $J = 8.9$ Hz, 2H), 6.72 (d, $J = 8.9$ Hz, 2H), 5.24 (s, 1H), 4.65 (s, 1H), 4.40 – 4.28 (m, 1H), 4.14 (t, $J = 4.6$ Hz, 2H), 4.10 (t, $J = 4.6$ Hz, 3H), 3.82 (d, $J = 4.6$ Hz, 2H), 3.77 (dd, $J = 5.5, 3.7$ Hz, 2H), 3.72 (q, $J = 3.1$ Hz, 2H), 3.66 (d, $J = 5.2$ Hz, 2H), 3.62 – 3.56 (m, 5H), 3.16 (h, $J = 3.5$ Hz, 1H), 3.05 (s, 6H), 3.04 (s, 6H), 2.96 – 2.90 (m, 1H), 2.78 (dd, $J = 12.8, 5.0$ Hz, 1H), 2.66 – 2.59 (m, 1H), 2.52 (m, 1H), 2.36 (q, $J = 7.1$ Hz, 2H), 1.85 – 1.80 (m, 1H), 1.67 (m, 6H), 1.58 (q, $J = 7.5$ Hz, 3H), 1.31 (d, $J = 16.4$ Hz, 3H). ^{13}C NMR (126 MHz, CDCl_3) $\delta = 172.8, 170.5, 169.2, 166.0, 163.1, 156.6, 152.5, 149.1, 135.8, 128.6, 122.9, 121.2, 116.0, 112.4, 106.5, 79.6, 69.7, 69.4, 69.2, 68.6, 61.66, 59.8, 59.8, 55.9, 55.6, 48.6, 46.1, 40.2, 40.2, 32.5, 30.6, 28.8, 28.7, 28.6, 28.4, 28.0, 26.0, 25.7, 25.4, 24.8$. HRMS (EI): m/z calcd for $[\text{M}+\text{H}]^+$ $\text{C}_{48}\text{H}_{58}\text{N}_7\text{O}_6\text{S}_3$ 924.3611. Found 924.3618.

Aggregation of α -synuclein

Monomeric wild-type α -synuclein was purified from *Escherichia coli* as previously described⁶³. Prior to use, α -synuclein aliquots were ultracentrifuged at 350000 g during 1h at 4 °C using TL120.2 rotor (Beckman) in a Optima TLX Ultracentrifuge (Beckman) to remove possible seed contaminants. 2/3 of the total volume in the tube was used as the supernatant fraction (monomers only) and removed with minimal perturbation to avoid remixing of unwanted seeds. Afterwards, the protein concentration was determined using a nanodrop ($\epsilon^{275\text{ nm}}$ (Tyr) 5600 $\text{M}^{-1}\text{cm}^{-1}$) and then the α -synuclein was diluted in cold Tris buffer 25 mM supplemented with NaCl 100 mM, pH 7.4 and 0.01% NaN_3 (to prevent bacterial growth) to a final concentration of 70 μM . This solution was incubated in the dark at 37 °C with constant agitation at 200 rpm (New Brunswick Scientific Innova 43) and aliquots were taken at desired times (0 h monomers, 6-8 h oligomers and 1-5 d for mature fibrils). All time points were imaged on TIRFM setup before any experiment to confirm the presence/absence of the desired α -synuclein intermediate species *i.e* absence of aggregates at t 0 h and fibrils on 6-8 h and presence of diffracted limited size aggregates on the 6-8 h time point aliquots. All steps were carried out using LoBind microcentrifuge tubes (Eppendorf, Hamburg, Germany) to limit surface adsorption.

Preparation and photophysical characterization of CAP-1

CAP-1 1mM stock solution was prepared in DMSO, divided into 20 μL aliquots and stored at -20 °C. Aliquots were used once to avoid freeze and thaw cycles. The photophysical properties of CAP-1 were determined using a Varian Cary Eclipse fluorescence spectrophotometer (Mulgrave, Australia). Experimental settings used were $\lambda_{\text{ex}} = 355$ nm (5 - 10 nm bandwidth), $\lambda_{\text{em}} = 370\text{-}600$ nm (5 - 10 nm bandwidth). UV-vis absorption and fluorescence (both excitation and emission) spectral characterization of CAP-1 (20 μM) were carried out in both PBS and Tris 25 mM supplemented with NaCl 100 mM, pH 7.4. For binding affinity experiments α -synuclein fibrils were sonicated on

a probe sonicator (Bandelin, Sonopuls HD 20170), 4 times of 15 s at 10% power and the tube was placed on a beaker containing ice to minimise overheating effects on the tube walls.

Amyloid precipitation assay – AP

The amyloid precipitation (AP) assay consists of the pulldown of protein aggregates (e.g. α -synuclein) using streptavidin-Dynabeads (MyOne™ Streptavidin C1, Invitrogen) conjugated with CAP-1. Briefly, 30 μ L of beads/sample were removed from the vial, resuspended in 1 mL PBS and placed on a magnet for 2-3 min for separation and the supernatant discarded (this step was repeated three times). Afterwards, the beads were resuspended in 1 mL of CAP-1 30 μ M and the tube placed in a revolver mixer for incubation at room temperature during 1h. Following, the tube was placed on the magnet for 2-3 min and the supernatant discarded. The beads were washed three times with PBS as before. Finally, the beads were resuspended in 500 μ L solution containing α -synuclein 10 μ M (monomers alone, or mixture of aggregates) and left in the revolver mix for 2h or overnight at 4 °C. In the end, the tube was placed on the magnet for 2-3 min and 450 μ L of supernatant were removed to a clean tube and labelled as ‘depleted’ fraction, both the depleted fraction and the ‘beads’ were kept at 4 °C until use. All steps were carried out in LoBind microcentrifuge tubes (Eppendorf, Hamburg, Germany) to limit surface adsorption.

Detection of bead-bound α -synuclein

After amyloid precipitation (AP) both ‘beads’ (diluted 1:32 in PBS) and the ‘depleted’ fraction were added to a 96-well half-area plate with clear bottom (Corning 3881, Kennebuck ME, USA) for bulk fluorescence measurement. The plate was placed in a plate reader (CLARIOstar; BMG Labtech, Ortenberg, Germany) and Fluorescence intensity (bottom reading) was measured straight away at room temperature using the following settings: end-point mode, 440-10/480-10 nm excitation and emission wavelengths respectively; or spectrum mode, excitation at 355 nm and emission from 380-600 nm.

Preparation of slides for single-molecule measurements

Borosilicate glass coverslips (VWR international, 20 × 20 mm, product number 631-0122) were cleaned using an argon plasma cleaner (PDC-002, Harrick Plasma) for 1 h to remove impurities and contaminants and create a hydrophilic surface. Frame-seal slide chambers (9 × 9 mm², Biorad, Hercules, CA, product number SLF-0601) were affixed to the glass, and 50 μ L of poly-L-lysine (70000-150000 molecular weight, Sigma-Aldrich, product number P4707-50 ML) was added to the coverslip on the inside of the chamber and incubated for 30 min before being washed with filtered

PBS buffer (Whatman Anatop 25 0.02 μm). Each batch of coverslips was tested for fluorescent artefacts (*i.e.* false positives) by imaging thioflavin T (ThT) 5 μM . ThT stock solution was prepared as described elsewhere³⁸ and ThT working solution (50-100 μM) was filtered (Whatman Anatop 25 0.02 μm) prior to use and concentration determined using $\epsilon^{412\text{ nm}} 36000\text{ M}^{-1}\text{cm}^{-1}$.

Total internal reflection fluorescence microscopy (TIRFM) imaging

Imaging was performed using a homebuilt total internal reflection fluorescence microscope as reported previously³⁸. Briefly, this imaging mode restricts detectable axial fluorescence signal to within $\sim 200\text{ nm}$ from the glass-water interface. For imaging of recombinant α -synuclein or cerebrospinal fluid (CSF) in the presence of ThT or CAP-1, the output from laser operating at 405 nm (Oxxius LaserBoxx, product number LBX-405-100-CIR-PP) was aligned and directed parallel to the optical axis at the edge of a 60 $\times$ Plan Apo TIRF, NA 1.45 oil objective, (Nikon Corporation), mounted an Eclipse TE2000-U microscope (Nikon Corporation) fitted with a Perfect Focus unit. Fluorescence was collected by the same objective and was separated from the returning TIR beam by a dichroic (Di01-R405/488/561/635, Semrock), and passed through appropriate filter (FF01-480/40-25 or FF01-434/17-25 Semrock, for ThT or CAP-1, respectively). The images were recorded on an EMCCD camera (Evolve 512, Photometrics) operating in frame transfer mode (EMGain of 6.5 e⁻/ADU and 250 ADU/photon). Each pixel was 241 nm in size. For each data set, 4 $\times$ 4 image grids were measured in at least three different regions of the coverslip. The distance between the nine images measured in each grid was set to 350 μm , and was automated (bean-shell script, Micromanager) to prevent user bias. Images were recorded at 50 ms exposure time for 100 frames with 405 nm illumination (150–200 W/ cm^2).

Recombinant α -synuclein and CSF were diluted in filtered PBS (Whatman Anatop 25 0.02 μm) and mixed with ThT or CAP-1 for a final imaging volume of 50 μL . The ThT and CAP-1 imaging concentration was 5 μM while the α -synuclein concentration changed between experiments (1 μM for sonicated fibrils, 2.8 μM for comparison of time points, and 7 μM for $t=8\text{h}$). For CSF samples, we used 15 μL of neat CSF and 24 μL of depleted fraction AP. All samples were stored and diluted in LoBind microcentrifuge (Eppendorf, Hamburg, Germany) to limit surface adsorption. For imaging the beads (Figure 2 c) we used 1 μL of ‘beads’ fraction (50 μL in total) in 49 μL of PBS.

AP of α -synuclein spiked in CSF followed by on-bead digestion

The CSF sample aliquots used were de-identified leftover aliquots from clinical routine analyses, following a procedure approved by the Ethics Committee at University of Gothenburg (EPN

140811). Amyloid precipitation was carried out as described above, except for using 50 μ L of beads per sample instead of 30 μ L. After conjugation with CAP-1 and washing the beads were resuspended in a solution containing 600 μ L of CSF and 400 μ L PBS. α -synuclein was spiked into the CSF, adding either monomer alone or a mixture containing monomers and oligomers (previously characterized using TIRFM). Concentrations spiked were 1 pM, 100 pM, 1 nM, 10 nM and 100 nM and samples were prepared in triplicate. The immunoprecipitation method for CSF samples was performed according to Bhattacharjee *et al.* 2019 with minor modifications^{64,65}. Briefly, after overnight incubation at 4 °C the KingFisher magnetic particle processor (Thermo Fisher Scientific) was used to wash and resuspend the beads. The beads were first extracted, then washed two times with PBS, one time with 1 mL of 50 mM ammonium bicarbonate (NH_4HCO_3 , pH 8.0; Sigma-Aldrich) and finally resuspended in 100 μ L of 50 mM NH_4HCO_3 for on-bead digestion. For on-bead digestion 10 μ L of 10 mM 1,4-dithiothreitol (DTT) in NH_4HCO_3 was added to the solution, vortexed and incubated for 30 min at 60 °C and, then cooled down to room temperature for 15 min. Afterwards, 10 μ L of 10 mM iodoacetamide (IAM) in NH_4HCO_3 was added, vortexed and incubated for 30 min at 25°C in darkness. Finally, 10 μ L of trypsin 5 ng/ μ L in NH_4HCO_3 was added, vortexed and incubated at 37°C overnight with shaking at 400 rpm. The reaction was stopped by addition of 10 μ L 10% formic acid (FA). Finally, samples were centrifuged at 16910 g for 10 min, 4 °C and the supernatant collected in a different vial. The magnetic beads were washed with 50 μ L NH_4HCO_3 , then centrifuged again and the supernatant was collected in the same vial as before. Then collected supernatants were dried by speedvac.

LC-MS/MS of α -synuclein

High-resolution parallel reaction monitoring (PRM) analyses were performed on a quadrupole–orbitrap mass spectrometer Q-Exactive (Thermo Fisher Scientific) coupled to an Ultimate 3000 chromatography system (Thermo Fisher Scientific). Mobile phases were 0.1% aqueous FA(v/v) (A) and 0.1% FA in 84% ACN in water (v/v) (B). The mixture of Heavy-isotope-labeled peptide standards of α -synuclein (Heavy Peptide FasTrack 1 standards, ThermoFisher Scientific, USA) was prepared in 20% ACN containing 0.1% FA as follows: α -syn₁₃₋₂₁, α -syn₃₅₋₄₃, α -syn₄₆₋₅₈, α -syn₆₁₋₈₀, and α -syn₈₁₋₉₆ (10 fmoles/ μ L each). Then the dried samples after pull down and on-bead digestion were dissolved in 20 μ L of mixture of heavy-isotope-labelled (IS) peptide standards for 1 h and then transferred to LC vials for analysis. Samples were loaded directly onto a HypersilGold-C18 column, (length 100 mm, inner diameter 2 mm, particle size 1.9 μ m, Thermo Fischer Scientific) with 0.1% aqueous FA at 300 μ L/min. After 2 min of loading, the peptides were eluted off the column using the following linear gradient steps: 0 min 0%B; 4 min 17%B; 16 min 35%B; 17.5 min 100%B; 20 min 0%B. The global MS parameters were: positive ion mode; spray voltage 3.5 kV; vaporizer

temperature +350°C; sheath gas pressure 40 psi; auxiliary gas pressure 25 arbitrary units; capillary temperature +350°C; collision gas pressure 1.9 mTorr. The instrument was set to acquire scheduled pairs or triplets of PRM scans and subsequent all ion fragmentation scans allowing simultaneous detection of both the α -synuclein peptide and the corresponding IS peptide standards. The settings were common for both scans types and were as follows: resolution, 70,000; AGC target, 3e6; maximum injection time, 250 ms; isolation window, 3.0 m/z and normalized collision energy 35. Data acquisition and analysis were performed with Xcalibur software version 2.2 SP1.48 (ThermoFisher Scientific) and Pinpoint 1.3.0 (ThermoFisher Scientific) for determining selected fragment ion peak areas, respectively. The MS accuracy was ± 10 ppm centred at 0, a MS/MS accuracy of ± 15 ppm and the isolation mode set to MS/MS with an isolation width of 3.0 u. The peaks were detected using a chromatographic peak with a window size of ± 2.0 min. The complete peak area was determined after using four points of smoothing. The scheduling window size for identified transitions was ± 0.5 min. The detected fragment ion peaks were manually inspected for accuracy and absence of interferences from other peptides than the peptide of interest, including fragments originating from other product ions in the same pair/triplet. The relative amount of spiked unlabelled or ^{15}N -labeled α -synuclein peptide was calculated by normalizing the measured peak area with the peak area of the corresponding IS peptide.

Database search parameters

Specified search parameters: database (Swiss-Prot), taxonomy (*Homo sapiens*), enzyme (trypsin), variable modifications (acetyl [N-term] and oxidation [M]), static modification (carbamidomethyl [C]), mass values (monoisotopic), peptide mass tolerance (± 10 ppm), fragment mass tolerance (± 10 mmu), and maximum 2 missed cleavages. On average, individual ions scores > 40 indicate identity or extensive homology ($P < 0.05$) was considered for identification. Ions score is $-10\log(P)$, where P is the probability that the observed match is a random event.

Membrane permeability assay

Details of this method have been described previously¹⁸. Studies have shown that single vesicle assay can be used to measure the toxicity of β -sheet rich protein aggregates present in CSF⁶⁶ or complex biological mixture²². Briefly, Phospholipids 16:0-18:1 1-palmitoyl-2-oleoyl-glycero-3-phosphocholinePC (Avanti Polar Lipids) and biotinylated lipids 1-oleoyl-2-[12-biotinyl(aminododecanoyl)]-sn-glycero-3-phosphocholine18:1-12:0 Biotin PC (Avanti Polar Lipids) were mixed 100:1 ratio and dissolved in HEPES buffer (pH 6.5) with 100 μM Cal-520. Using dry ice and a water bath, five freeze-and-thaw cycles were performed to control the unilamellarity. Then the mixed lipid solution was passed 10 times through an extruder (Avanti Polar

Lipids, A) with a membrane of 200 nm diameter. To remove the free dye from the surrounding solution containing dye-filled vesicles, size-exclusion chromatography was performed using Superdex 200. The size of the vesicles was confirmed using a zeta-sizer. The vesicles are immobilised using biotin-neutravidin linkage in glass coverslips. Before immobilisation of the vesicles, each coverslip is cleaned using argon based plasma cleaner and sample chambers were made by affixing Frame-Seal incubation chambers onto the glass slides. For homogeneous surface treatment, 50 μ L of a mixture of 100:1 PLL-g-PEG and PLL-g-PEG biotin (both 1 g/L) in HEPES buffer (50 mM, pH 6.5) was added to the coverslip inside of the chamber and incubated for 30 min. Then the surface was washed with filtered HEPES buffer and a solution of NeutrAvidin (50 μ L of 0.1 mg/mL in MilliQ) added and incubated for 15 min before being washed. 50 μ L of vesicles was added to the coverslip and let to adsorb for 20 min before solution is removed and replaced by 30 μ L of Ca^{2+} containing buffer solution Leibovitz's L-15 and background image was recorded ($F_{\text{background}}$). Thereafter, 16 μ L of sample (16 μ L of AP depleted fraction or 10 μ L of neat CSF + 6 μ L PBS) was added and incubated for 20 min and images were acquired (F_{sample}). Next, 10 μ L of ionomycin solution added and same fields of view were acquired ($F_{\text{ionomycin}}$). For each field of view (10 to 15 in total) 50 images were taken with an exposure time of 50 ms. The relative Ca^{2+} influx into an individual vesicle due to protein aggregates present in CSF was then determined as

$$\text{Ca}^{2+}\text{influx} = \frac{F_{\text{sample}} - F_{\text{background}}}{F_{\text{ionomycin}} - F_{\text{background}}}$$

The average degree of was calculated by averaging the Ca^{2+} influx into individual vesicles. The membrane permeabilization experiments were performed using a homebuilt TIRF imaging setup microscope using 1.49 100 $\times$ Nikon TIRF Objective. For excitation 488-nm laser (Toptica) beam and images were acquired using an air-cooled EMCCD camera (Evolve Delta).

Data analysis

Microscopy images were analysed using ImageJ and Matlab. GraphPad Prism 8 was used for statistical analysis, plotting and curve fitting. Statistical analysis was performed using unpaired two-tailed Student's t test to analyse differences between two groups, or a one-way ANOVA and Tukey's *post hoc* comparison to analyse differences among three or more groups. Differences were considered to be statistically significant if $p < 0.05$. To determine the number of fluorescent puncta in each image an average of the entire stack was generated and used to detect each protein aggregate using the Find Maxima function in ImageJ (with a threshold value of 180 Figure 2e). To compare proteins pulled down from control (A) and PD (B) CSF in the presence (1) and absence (2) of CAP-1 we used a custom Matlab code (available on request). From the original database search (Swiss-Prot) we generated new data sets for each condition (A1, A2, B1 and B2) based on 2 criteria: proteins

present in all three replicates and with at least 2 unique peptides. Then we compared list A1 with A2 and B1 with B2. See SI Table 3 – 8 for results: List of common proteins (Table 3 (A1-A2) and Table 6 (B1-B2)) and list of exclusive proteins (Table 4 (A1), Table 5 (A2), Table 7 (B1) and Table 8 (B2)). Finally, we used PASTA 2.0⁴⁵ (Table 1-8) and RFAmyloid⁴⁶ (Table 9), two bioinformatic tools to predict % of α -helix and % of β -strand, and amyloid formation, from protein sequence analysis, respectively.

Acknowledgements

HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931) and the UK Dementia Research Institute at UCL. DK is supported by grants from the European Research Council (#669237), the Royal Society and UK Dementia Research Institute at Cambridge. We thank the Royal Society for the University Research Fellowship to SFL (UF120277), TNS: National Institutes of Health (R01GM121573). Also, Michael J. Fox Grant to SFL and TNS (grant ID: 10200). JAV is supported by the European Research Council with an ERC Starting Grant (804581).

Competing Interests

HZ has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg (outside submitted work).

References

1. Knowles, T. P. J., Vendruscolo, M. & Dobson, C. M. The amyloid state and its association with protein misfolding diseases. *Nature Reviews Molecular Cell Biology* vol. 15 384–396 (2014).
2. Braak, H. *et al.* Pattern of brain destruction in Parkinson's and Alzheimer's diseases. *J. Neural Transm.* **103**, 455–490 (1996).
3. Goedert, M. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled A β , tau, and α -synuclein. *Science* (80-.). **349**, 61–69 (2015).
4. Scheltens, P. *et al.* Alzheimer's disease. *Lancet* **388**, 505–517 (2016).
5. Eisele, Y. S. *et al.* Peripherally Applied A β -Containing Inoculates Induce Cerebral β -Amyloidosis. *Science* (80-.). **330**, 980–982 (2010).
6. Meyer-Luehmann, M. *et al.* Exogenous induction of cerebral β -amyloidogenesis is governed by agent and host. *Science* (80-.). **313**, 1781–1784 (2006).
7. Luk, K. C. *et al.* Intracerebral inoculation of pathological α -synuclein initiates a rapidly progressive neurodegenerative α -synucleinopathy in mice. *J. Exp. Med.* **209**, 975–988 (2012).
8. Karampetsou, M. *et al.* Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice. *Sci. Rep.* **7**, 1–18 (2017).
9. Duran-Aniotz, C. *et al.* Aggregate-depleted brain fails to induce A β deposition in a mouse model of Alzheimer's disease. *PLoS One* **9**, (2014).
10. Morales, R., Bravo-Alegria, J., Duran-Aniotz, C. & Soto, C. Titration of biologically active amyloid- β seeds in a transgenic mouse model of Alzheimer's disease. *Sci. Rep.* **5**, 1–8 (2015).
11. Condello, C. *et al.* Structural heterogeneity and intersubject variability of A β in familial and sporadic Alzheimer's disease. *Proc. Natl. Acad. Sci. U. S. A.* **115**, E782–E791 (2018).
12. Lázaro, D. F. *et al.* Systematic Comparison of the Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation. *PLoS Genet.* **10**, (2014).
13. Tosatto, L. *et al.* Single-molecule FRET studies on alpha-synuclein oligomerization of Parkinson's disease genetically related mutants. *Sci. Rep.* **5**, 1–12 (2015).
14. Boyer, D. R. *et al.* The α -synuclein hereditary mutation E46K unlocks a more stable, pathogenic fibril structure. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 3592–3602 (2020).
15. Lee, J. E. *et al.* Mapping Surface Hydrophobicity of α -Synuclein Oligomers at the Nanoscale. *Nano Lett.* **18**, 7494–7501 (2018).
16. Cremades, N. *et al.* Direct observation of the interconversion of normal and toxic forms of α -synuclein. *Cell* **149**, 1048–1059 (2012).

17. Outeiro, T. F. *et al.* Formation of toxic oligomeric α -synuclein species in living cells. *PLoS One* **3**, 1–9 (2008).
18. Flagmeier, P. *et al.* Ultrasensitive Measurement of Ca^{2+} Influx into Lipid Vesicles Induced by Protein Aggregates. *Angew. Chemie - Int. Ed.* **56**, 7750–7754 (2017).
19. Ludtmann, M. H. R. *et al.* α -synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson's disease. *Nat. Commun.* **9**, 2293 (2018).
20. Whiten, D. R. *et al.* Single-Molecule Characterization of the Interactions between Extracellular Chaperones and Toxic α -Synuclein Oligomers. *Cell Rep.* **23**, 3492–3500 (2018).
21. Mannini, B. *et al.* Stabilization and Characterization of Cytotoxic A β 40 Oligomers Isolated from an Aggregation Reaction in the Presence of Zinc Ions. *ACS Chem. Neurosci.* **9**, 2959–2971 (2018).
22. De, S. *et al.* Different soluble aggregates of A β 42 can give rise to cellular toxicity through different mechanisms. *Nat. Commun.* **10**, (2019).
23. Esteras, N. *et al.* Insoluble tau aggregates induce neuronal death through modification of membrane ion conductance, activation of voltage-gated calcium channels and NADPH oxidase. *FEBS J.* 1–15 (2020) doi:10.1111/febs.15340.
24. De, S. *et al.* Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression. *Acta Neuropathol. Commun.* **7**, 113–120 (2019).
25. Kumar, S. T., Donzelli, S., Chiki, A., Syed, M. M. K. & Lashuel, H. A. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α -synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α -synuclein research. *J. Neurochem.* **153**, 103–119 (2020).
26. Iadanza, M. G., Jackson, M. P., Hewitt, E. W., Ranson, N. A. & Radford, S. E. A new era for understanding amyloid structures and disease. *Nat. Rev. Mol. Cell Biol.* **19**, 755–773 (2018).
27. MD, D. B. M. *et al.* α -Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. *Lancet Neurol.* **10**, 230–240 (2011).
28. Vaikath, N. N. *et al.* Antibodies against alpha-synuclein: tools and therapies. *J. Neurochem.* **150**, 612–625 (2019).
29. Mitkevich, O. V. *et al.* DNA aptamers detecting generic amyloid epitopes. *Prion* **6**, 400–406 (2012).
30. Rahimi, F. Aptamers selected for recognizing amyloid β -protein—a case for cautious optimism. *Int. J. Mol. Sci.* **19**, 1–20 (2018).

31. Bondarev, S. A., Antonets, K. S., Kajava, A. V., Nizhnikov, A. A. & Zhouravleva, G. A. Protein co-aggregation related to amyloids: Methods of investigation, diversity, and classification. *Int. J. Mol. Sci.* **19**, 1–30 (2018).
32. Juhl, D. W. *et al.* Conservation of the Amyloid Interactome Across Diverse Fibrillar Structures. *Sci. Rep.* **9**, 1–14 (2019).
33. Voropai, E. S. *et al.* Spectral properties of thioflavin T and its complexes with amyloid fibrils. *J. Appl. Spectrosc.* **70**, 868–874 (2003).
34. Biancalana, M. & Koide, S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. *Biochim. Biophys. Acta - Proteins Proteomics* **1804**, 1405–1412 (2010).
35. Klunk, W. E. *et al.* Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. *Life Sci.* **69**, 1471–1484 (2001).
36. Wu, C., Bowers, M. T. & Shea, J.-E. On the Origin of the Stronger Binding of PIB over Thioflavin T to Protofibrils of the Alzheimer Amyloid- β ; Peptide: A Molecular Dynamics Study. *Biophysj* **100**, 1316–1324 (2011).
37. Qin, L., Vastl, J. & Gao, J. Highly sensitive amyloid detection enabled by thioflavin T dimers. *Mol. Biosyst.* **6**, 1791–1795 (2010).
38. Horrocks, M. H. *et al.* Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids. *ACS Chem. Neurosci.* **7**, 399–406 (2016).
39. Ye, L. *et al.* In vitro high affinity α -synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. *J. Neurochem.* **105**, 1428–1437 (2008).
40. Sulatskaya, A. I. *et al.* Investigation of α -synuclein amyloid fibrils using the fluorescent probe thioflavin T. *Int. J. Mol. Sci.* **19**, (2018).
41. De, S. *et al.* Different soluble aggregates of A β 42 can give rise to cellular toxicity through different mechanisms. *Nat. Commun.* **10**, 1511–1541 (2019).
42. Xiong, F., Ge, W. & Ma, C. Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer's disease. *Alzheimer's Dement.* 1–12 (2018).
43. Heywood, W. E. *et al.* Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. *Mol. Neurodegener.* 1–16 (2015).
44. Guldbrandsen, A. *et al.* In-depth characterization of the cerebrospinal fluid (CSF) proteome displayed through the CSF proteome resource (CSF-PR). *Mol. Cell. Proteomics* **13**, 3152–3163 (2014).
45. Walsh, I., Seno, F., Tosatto, S. C. E. & Trovato, A. PASTA 2.0: An improved server for protein aggregation prediction. *Nucleic Acids Res.* **42**, 301–307 (2014).

46. Niu, M., Li, Y., Wang, C. & Han, K. RFamyloid: A web server for predicting amyloid proteins. *Int. J. Mol. Sci.* **19**, (2018).
47. Selkoe, D. J. The molecular pathology of Alzheimer's disease. *Neuron* **6**, 487–498 (1991).
48. Bruggink, K. A., Müller, M., Kuiperij, H. B. & Verbeek, M. M. Methods for analysis of amyloid- β aggregates. *J. Alzheimer's Dis.* **28**, 735–758 (2012).
49. Schuster, J. & Funke, S. A. Methods for the Specific Detection and Quantitation of Amyloid- β Oligomers in Cerebrospinal Fluid. *J. Alzheimer's Dis.* **53**, 53–67 (2016).
50. Soto, C. & Pritzkow, S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. *Nat. Neurosci.* **21**, 1332–1340 (2018).
51. Strømmand, Ø., Kakubec, M. & Halskau, Ø. Detection of mis-folded protein aggregates from a clinical perspective. *J. Clin. Transl. Res.* **1**, 11–26 (2016).
52. Blennow, K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. *NeuroRX* **1**, 213–225 (2004).
53. Klunk, W. E. *et al.* Imaging Brain Amyloid in Alzheimer's Disease with Pittsburgh Compound-B. *Ann. Neurol.* **55**, 306–319 (2004).
54. Mintun, M. A. *et al.* [11C]PIB in a nondemented population. *Neurology* **67**, 446–452 (2006).
55. Kramer, R. H. & Karpen, J. W. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. *Nature* **395**, 710–713 (1998).
56. Liang, J. *et al.* Dimerization of α -Conotoxins as a Strategy to Enhance the Inhibition of the Human $\alpha 7$ and $\alpha 9\alpha 10$ Nicotinic Acetylcholine Receptors. *J. Med. Chem.* **63**, 2974–2985 (2020).
57. Hühmer, A. F., Biringer, R. G., Amato, H., Fonteh, A. N. & Harrington, M. G. Protein analysis in human cerebrospinal fluid: Physiological aspects, current progress and future challenges. *Dis. Markers* **22**, 3–26 (2006).
58. Gu, X. *et al.* Molecular modeling and affinity determination of scFv antibody: Proper linker peptide enhances its activity. *Ann. Biomed. Eng.* **38**, 537–549 (2010).
59. Silacci, M. *et al.* Linker length matters, Fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency. *J. Biol. Chem.* **289**, 14392–14398 (2014).
60. Wang, W., Singh, S., Zeng, D. L., King, K. & Nema, S. Antibody Structure, Instability, and Formulation. *J. Pharm. Sci.* **96**, 1–26 (2007).
61. Zheng, S. *et al.* Investigating the Degradation Behaviors of a Therapeutic Monoclonal Antibody Associated with pH and Buffer Species. *AAPS PharmSciTech* **18**, 42–48 (2017).
62. Le Basle, Y., Chennell, P., Tokhadze, N., Astier, A. & Sautou, V. Physicochemical Stability of Monoclonal Antibodies: A Review. *J. Pharm. Sci.* **109**, 169–190 (2020).

63. Hoyer, W. *et al.* Dependence of α -synuclein aggregate morphology on solution conditions. *J. Mol. Biol.* **322**, 383–393 (2002).
64. Bhattacharjee, P. *et al.* Mass Spectrometric Analysis of Lewy Body-Enriched α -Synuclein in Parkinson's Disease. *J. Proteome Res.* **18**, 2109–2120 (2019).
65. Brinkmalm, A., Öhrfelt, A., Bhattacharjee, P. & Zetterberg, H. Detection of α -Synuclein in Biological Samples Using Mass Spectrometry BT - Alpha-Synuclein: Methods and Protocols. in *Alpha-Synuclein: Methods and Protocols* vol. 1948 (Springer New York, 2019).
66. Drews, A. *et al.* Inhibiting the Ca²⁺ Influx Induced by Human CSF. *Cell Rep.* **21**, 3310–3316 (2017).

Figures

Figure 1

[Please see the manuscript file to view the figure caption.]

Figure 2

[Please see the manuscript file to view the figure caption.]

Figure 3

[Please see the manuscript file to view the figure caption.]

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [MRmanuscriptSI.pdf](#)